Evidence map›Paper›PMID 1671652›Full record

ArticleBMJ (Clinical research ed.)1991

Use of secondary prophylaxis against myocardial infarction in the north of England.

M Eccles, C Bradshaw

Open access · bronzeAbstract read
In one paragraph

Article in BMJ (Clinical research ed.), 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
21.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease.The British journal of general practice : the journal of the Royal College of General Practitioners · 2001
    Article
  10. Review
  11. Aspirin use in middle-aged men with cardiovascular disease: are opportunities being missed?The British journal of general practice : the journal of the Royal College of General Practitioners · 1997
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Audit: the third clinical science?Quality in health care : QHC · 1992
    Article
  17. The economics of prescribing.Journal of the Royal College of Physicians of London · 1992
    Article
  18. Secondary prophylaxis against myocardial infarction.BMJ (Clinical research ed.) · 1991
    Article
  19. Secondary prophylaxis against myocardial infarction.BMJ (Clinical research ed.) · 1991
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

M EcclesCentre for Health Services Research, University of Newcastle upon Tyne.
C Bradshaw
Newcastle University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo record the use of secondary prophylactic drugs in patients discharged from hospital having had a myocardial infarction.

designProspective postal questionnaire survey of a random one in two sample of general practitioners in the region.

settingThe nine family practitioner committee areas within the Northern Regional Health Authority. PATIENTS: Patients who had had a myocardial infarction and were discharged to their general practitioner.

main outcome measureWhether beta blockers or aspirin, or both, were given on discharge.

resultsOf 267 patients, 158 (59%) were treated suboptimally in that they did not receive a secondary prophylactic drug to which they had no contraindication. For most patients this entailed underuse of one drug, but 17 (6%) of patients received no treatment. beta Blockers were 2.5 times less likely to be used than aspirin. Treatment was not associated with the age or sex of the patient, risk of further infarction, or hospital of discharge.

conclusionsSecondary prophylaxis after myocardial infarction is practised haphazardly. It should be offered to all patients who can tolerate it, after a trial period to assess any side effects of the drugs if necessary.

Indexed as

Adrenergic beta-AntagonistsAspirinContraindicationsDeath, SuddenDrug Therapy, CombinationEnglandFamily PracticeFemaleHumansMaleMyocardial InfarctionProspective StudiesRisk FactorsAdrenergic beta-AntagonistsAspirin

Identifiers

PMID1671652
PMCPMC1668878
OpenAlexW2008789150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.